ArmaGen Update on Hurler Syndrome Development Program

AGT-181: Investigational Therapy for the Treatment of Patients with Hurler Syndrome AGT-181 is an investigational enzyme replacement therapy designed to treat both the body-related and central nervous system-related symptoms and complications of MPS I. Currently approved treatments for MPS I are unable to penetrate the blood-brain barrier (BBB), a filter that protects the brain from harmful substances like toxins and bacteria but allows [...]